{"pmid":32498972,"pmcid":"PMC7254005","title":"SARS-CoV2 RNA detection in a pancreatic pseudocyst sample.","text":["SARS-CoV2 RNA detection in a pancreatic pseudocyst sample.","The involvement of gastrointestinal system in SARS-CoV2 related disease, COVID-19, is increasingly recognized. COVID-19 associated pancreatic injury has been suggested, but its correlation with pancreatic disease is still unclear. In this case report, we describe the detection of SARS-CoV2 RNA in a pancreatic pseudocyst fluid sample collected from a patient with SARS-CoV2 associated pneumonia and a pancreatic pseudocyst developed as a complication of an acute edematous pancreatitis. The detection of SARS-CoV2 within the pancreatic collection arise the question of whether this virus has a tropism for pancreatic tissue and whether it plays a role in pancreatic diseases occurrence.","Pancreatology","Schepis, T","Larghi, A","Papa, A","Miele, L","Panzuto, F","De Biase, L","Annibale, B","Cattani, P","Rapaccini, G L","32498972"],"abstract":["The involvement of gastrointestinal system in SARS-CoV2 related disease, COVID-19, is increasingly recognized. COVID-19 associated pancreatic injury has been suggested, but its correlation with pancreatic disease is still unclear. In this case report, we describe the detection of SARS-CoV2 RNA in a pancreatic pseudocyst fluid sample collected from a patient with SARS-CoV2 associated pneumonia and a pancreatic pseudocyst developed as a complication of an acute edematous pancreatitis. The detection of SARS-CoV2 within the pancreatic collection arise the question of whether this virus has a tropism for pancreatic tissue and whether it plays a role in pancreatic diseases occurrence."],"journal":"Pancreatology","authors":["Schepis, T","Larghi, A","Papa, A","Miele, L","Panzuto, F","De Biase, L","Annibale, B","Cattani, P","Rapaccini, G L"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498972","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.pan.2020.05.016","keywords":["covid-19","endoscopic drainage","pancreatic pseudocyst","sars-cov2"],"topics":["Diagnosis"],"weight":1,"_version_":1668890966359015424,"score":9.490897,"similar":[{"pmid":32497298,"title":"Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence.","text":["Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence.","Despite respiratory symptoms are typically found during the course of coronavirus disease 2019 (COVID-19), gastrointestinal manifestations are increasingly described. However, data regarding COVID-19-associated pancreatic injury are still limited, as well as the mechanisms underlying COVID-19 induced-pancreatic damage have not been completely clarified. Herein, we described pancreatic abnormalities in six (8.5%) out of 70 patients with COVID-19 hospitalized in our unit from February 25, 2020 to May 10, 2020. We hypothesized that pancreatic damage may be associated with several factors including direct effect of SARS-CoV-2, inflammatory cascade, dehydration and multiple organ dysfunction. This article is protected by copyright. All rights reserved.","J Med Virol","Bruno, Giuseppe","Fabrizio, Claudia","Santoro, Carmen Rita","Buccoliero, Giovanni Battista","32497298"],"abstract":["Despite respiratory symptoms are typically found during the course of coronavirus disease 2019 (COVID-19), gastrointestinal manifestations are increasingly described. However, data regarding COVID-19-associated pancreatic injury are still limited, as well as the mechanisms underlying COVID-19 induced-pancreatic damage have not been completely clarified. Herein, we described pancreatic abnormalities in six (8.5%) out of 70 patients with COVID-19 hospitalized in our unit from February 25, 2020 to May 10, 2020. We hypothesized that pancreatic damage may be associated with several factors including direct effect of SARS-CoV-2, inflammatory cascade, dehydration and multiple organ dysfunction. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Bruno, Giuseppe","Fabrizio, Claudia","Santoro, Carmen Rita","Buccoliero, Giovanni Battista"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32497298","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26134","keywords":["covid-19","increased lipase","pancreatic injury"],"topics":["Mechanism"],"weight":1,"_version_":1668712823917641728,"score":395.24445},{"pmid":32377176,"pmcid":"PMC7201379","title":"Pancreatic Cancer During COVID-19 Pandemic: Treat or Not to Treat?","text":["Pancreatic Cancer During COVID-19 Pandemic: Treat or Not to Treat?","Pancreatic cancer is a very aggressive disease and survival remains dismal even with treatment. Currently, management of patients with pancreatic cancer has been complicated by the ongoing COVID-19 pandemic. Medical oncologists face the dilemma of whether to treat or to not treat these patients who are at high-risk of complications and even death from COVID-19. No current guidelines are available and our limited experience at this time makes it more difficult to manage these patients. Although we have general strategies available from experience in Italy, we need more treatment specific strategies to help mitigate risks of complications and toxicities from chemotherapy in order to protect our patients from COVID-19 as much as possible.","JOP","Patel, Rajvi","Saif, Wasif","32377176"],"abstract":["Pancreatic cancer is a very aggressive disease and survival remains dismal even with treatment. Currently, management of patients with pancreatic cancer has been complicated by the ongoing COVID-19 pandemic. Medical oncologists face the dilemma of whether to treat or to not treat these patients who are at high-risk of complications and even death from COVID-19. No current guidelines are available and our limited experience at this time makes it more difficult to manage these patients. Although we have general strategies available from experience in Italy, we need more treatment specific strategies to help mitigate risks of complications and toxicities from chemotherapy in order to protect our patients from COVID-19 as much as possible."],"journal":"JOP","authors":["Patel, Rajvi","Saif, Wasif"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32377176","source":"PubMed","week":"202019|May 04 - May 10","keywords":["adjuvant chemotherapy","covid-19, pandemics","lymphopenia","neutropenia","pancreatic cancer"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666262687572557825,"score":304.86932},{"pmid":32423899,"title":"ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.","text":["ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.","The COVID-19 pandemic is challenging the capacities of health systems in many countries. National healthcare services have to manage unexpected shortages of healthcare resources that have to be re-allocated according to the principles of fair and ethical prioritisation, in order to maintain the highest levels of care to all patients, ensure the safety of patients and healthcare workers, and save as many lives as possible. Also, cancer care services have to pursue restructuring, following the same evidence-based dispositions. In this article, we propose a guidance to the management of pancreatic cancer during the pandemic, prioritised according to a three-tiered framework, and based on expert clinical judgement and magnitude of benefit expected from specific interventions. Since the availability of resources for diagnostic procedures, surgery and postoperative care, systemic therapy and radiotherapy may differ, the authors have separated the prioritisation analyses. The impact of postponing or abrogating cancer interventions on outcomes according to a high, medium or low priority scale is outlined and discussed. The implementation of healthcare services using telemedicine is explored; it reveals itself as functional and effective for limiting patients' need to travel to centres and thereby has the potential to reduce diffusion of SARS-CoV-2. Pancreatic cancer demands a considerable amount of medical resources. Therefore, the redefinition of its diagnostic and therapeutic algorithms with a rigorous method is crucial in order to ensure the highest quality of continuum of care in the broader context of the pandemic and the challenged healthcare systems.","ESMO Open","Catanese, Silvia","Pentheroudakis, George","Douillard, Jean-Yves","Lordick, Florian","32423899"],"abstract":["The COVID-19 pandemic is challenging the capacities of health systems in many countries. National healthcare services have to manage unexpected shortages of healthcare resources that have to be re-allocated according to the principles of fair and ethical prioritisation, in order to maintain the highest levels of care to all patients, ensure the safety of patients and healthcare workers, and save as many lives as possible. Also, cancer care services have to pursue restructuring, following the same evidence-based dispositions. In this article, we propose a guidance to the management of pancreatic cancer during the pandemic, prioritised according to a three-tiered framework, and based on expert clinical judgement and magnitude of benefit expected from specific interventions. Since the availability of resources for diagnostic procedures, surgery and postoperative care, systemic therapy and radiotherapy may differ, the authors have separated the prioritisation analyses. The impact of postponing or abrogating cancer interventions on outcomes according to a high, medium or low priority scale is outlined and discussed. The implementation of healthcare services using telemedicine is explored; it reveals itself as functional and effective for limiting patients' need to travel to centres and thereby has the potential to reduce diffusion of SARS-CoV-2. Pancreatic cancer demands a considerable amount of medical resources. Therefore, the redefinition of its diagnostic and therapeutic algorithms with a rigorous method is crucial in order to ensure the highest quality of continuum of care in the broader context of the pandemic and the challenged healthcare systems."],"journal":"ESMO Open","authors":["Catanese, Silvia","Pentheroudakis, George","Douillard, Jean-Yves","Lordick, Florian"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423899","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/esmoopen-2020-000804","keywords":["covid-19 pandemic"],"topics":["Prevention"],"weight":1,"_version_":1667252837840584704,"score":252.79883},{"pmid":32369475,"title":"[Recommendations of the Society of Gastroenterology of Peru to avoid the spread of SARS-CoV-2 through digestive endoscopy procedures].","text":["[Recommendations of the Society of Gastroenterology of Peru to avoid the spread of SARS-CoV-2 through digestive endoscopy procedures].","The SARS-CoV-2 coronavirus produces the disease called COVID-19, currently spreading in a rapidly evolving pandemic. It can be transmitted by contact, drops and aerosols, and has been isolated from gastrointestinal secretions and faeces. During digestive endoscopy, transmission by any of these mechanisms could occur. It is recommended to limit digestive endoscopy to cases of digestive bleeding, severe dysphagia, foreign body in the digestive tract, biliary obstruction with intractable pain or cholangitis, pseudocyst or complicated encapsulated pancreatic necrosis, gastrointestinal obstruction, and cases at risk of deterioration over time. It is recommended to screen patients based on temperature, symptoms, and epidemiological factors to classify them according to their risk of infection. For procedures in low risk patients, personnel must wear a disposable gown, gloves, eye or face shield, standard surgical mask, disposable hat, disposable shoe covers. In cases of intermediate or high risk, or confirmed COVID-19, protection should be increased using disposable waterproof gown, N95 respirator or similar, and double glove. In case of shortage it may be necessary to reuse N95 respirators for up to 5 uses, following CDC recommendations for donning, removing and storing to prevent secondary contact contamination. Likewise, all protective equipment should be put on and removed according to CDC recommendations. The presence of personnel in endoscopy should be limited to the bare minimum. Said personnel must have daily temperature control and if it is above 37.3 masculineC, the corresponding evaluation must be carried out. After each procedure, the stretcher and room surfaces should be properly disinfected. High-level disinfection of endoscopes eliminates SARS-CoV-2.","Rev Gastroenterol Peru","Prochazka Za Rate, Ricardo Arturo","Cabrera Cabrejos, Maria Cecilia","Piscoya, Alejandro","Vera Calderon, Augusto Francisco","32369475"],"abstract":["The SARS-CoV-2 coronavirus produces the disease called COVID-19, currently spreading in a rapidly evolving pandemic. It can be transmitted by contact, drops and aerosols, and has been isolated from gastrointestinal secretions and faeces. During digestive endoscopy, transmission by any of these mechanisms could occur. It is recommended to limit digestive endoscopy to cases of digestive bleeding, severe dysphagia, foreign body in the digestive tract, biliary obstruction with intractable pain or cholangitis, pseudocyst or complicated encapsulated pancreatic necrosis, gastrointestinal obstruction, and cases at risk of deterioration over time. It is recommended to screen patients based on temperature, symptoms, and epidemiological factors to classify them according to their risk of infection. For procedures in low risk patients, personnel must wear a disposable gown, gloves, eye or face shield, standard surgical mask, disposable hat, disposable shoe covers. In cases of intermediate or high risk, or confirmed COVID-19, protection should be increased using disposable waterproof gown, N95 respirator or similar, and double glove. In case of shortage it may be necessary to reuse N95 respirators for up to 5 uses, following CDC recommendations for donning, removing and storing to prevent secondary contact contamination. Likewise, all protective equipment should be put on and removed according to CDC recommendations. The presence of personnel in endoscopy should be limited to the bare minimum. Said personnel must have daily temperature control and if it is above 37.3 masculineC, the corresponding evaluation must be carried out. After each procedure, the stretcher and room surfaces should be properly disinfected. High-level disinfection of endoscopes eliminates SARS-CoV-2."],"journal":"Rev Gastroenterol Peru","authors":["Prochazka Za Rate, Ricardo Arturo","Cabrera Cabrejos, Maria Cecilia","Piscoya, Alejandro","Vera Calderon, Augusto Francisco"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369475","source":"PubMed","week":"202019|May 04 - May 10","locations":["Peru"],"countries":["Peru"],"countries_codes":["PER|Peru"],"topics":["Prevention"],"weight":1,"_version_":1666138496193003523,"score":245.04045},{"pmid":32366279,"pmcid":"PMC7197362","title":"Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis.","text":["Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis.","The novel coronavirus (2019-nCoV) is an emerging causative agent that was first described in late December 2019 and causes a severe respiratory infection in humans. Notably, many of affected patients of COVID-19 were people with malignancies. Moreover, cancer has been identified as an individual risk factor for COVID-19. In addition, the expression of angiotensin converting enzyme 2 (ACE2), the receptor of COVID-19, were aberrantly expressed in many tumors. However, a systematic analysis of ACE2 aberration remained to be elucidated in human cancers. Here, we analyzed genetic alteration, RNA expression, and DNA methylation of ACE2 across over 30 tumors. Notably, overexpression of ACE2 have been observed in including colon adenocarcinoma (COAD), kidney renal papillary cell carcinoma (KIRP), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), and lung adenocarcinoma (LUAD). In addition, hypo DNA methylation of ACE2 has also been identified in most of these ACE2 highly expressed tumors. Conclusively, our study for the first time curated both genetic and epigenetic variations of ACE2 in human malignancies. Notably, because our study is a bioinformatics assay, further functional and clinical validation is warranted.","J Hematol Oncol","Chai, Peiwei","Yu, Jie","Ge, Shengfang","Jia, Renbing","Fan, Xianqun","32366279"],"abstract":["The novel coronavirus (2019-nCoV) is an emerging causative agent that was first described in late December 2019 and causes a severe respiratory infection in humans. Notably, many of affected patients of COVID-19 were people with malignancies. Moreover, cancer has been identified as an individual risk factor for COVID-19. In addition, the expression of angiotensin converting enzyme 2 (ACE2), the receptor of COVID-19, were aberrantly expressed in many tumors. However, a systematic analysis of ACE2 aberration remained to be elucidated in human cancers. Here, we analyzed genetic alteration, RNA expression, and DNA methylation of ACE2 across over 30 tumors. Notably, overexpression of ACE2 have been observed in including colon adenocarcinoma (COAD), kidney renal papillary cell carcinoma (KIRP), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), and lung adenocarcinoma (LUAD). In addition, hypo DNA methylation of ACE2 has also been identified in most of these ACE2 highly expressed tumors. Conclusively, our study for the first time curated both genetic and epigenetic variations of ACE2 in human malignancies. Notably, because our study is a bioinformatics assay, further functional and clinical validation is warranted."],"journal":"J Hematol Oncol","authors":["Chai, Peiwei","Yu, Jie","Ge, Shengfang","Jia, Renbing","Fan, Xianqun"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366279","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1186/s13045-020-00883-5","keywords":["ace2","covid-19","expression"],"topics":["Mechanism"],"weight":1,"_version_":1666138496150011905,"score":186.46402}]}